D. E. Shaw & Co., Inc. Bei Gene, Ltd. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,600 shares of BGNE stock, worth $362,736. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,600

Previous 140,574 98.86%

Holding current value

$362,736

Previous $31.9 Million 98.86%

% of portfolio

0.0%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	N/A	17,626 Added 12.54%	158,200 $35.9 Million
Q1 2025 May 15, 2025	BUY	$175.1 - $226.71 $24.6 Million - $31.9 Million	140,574 New	140,574 $31.9 Million
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $432,693 - $549,708	2,727 New	2,727 $491,000
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $13.3 Million - $19.5 Million	-51,120 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $11.3 Million - $16.2 Million	51,120 New	51,120 $13.2 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $645,541 - $798,018	-5,256 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $431,464 - $706,204	4,032 Added 329.41%	5,256 $737,000
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $319,586 - $397,148	-2,094 Reduced 63.11%	1,224 $211,000
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $541,070 - $769,099	-3,548 Reduced 51.67%	3,318 $510,000
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $1.05 Million - $1.51 Million	-13,173 Reduced 65.74%	6,866 $671,000
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $1.33 Million - $2.07 Million	20,039	20,039 $2.07 Million

Others Institutions Holding BGNE

# of Institutions

283

Shares Held

32.2M

Call Options Held

113K

Put Options Held

106K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account